William Carson Net Worth

William Carson biography

Dr. William H. Carson M.D. serves as Director of the Company. has served as Chairman of Otsuka Pharmaceutical Development & Commercialization, Inc. (“OPDC”) since January 2020 and previously served as President and Chief Executive Officer of OPDC from 2010 to January 2020. Dr. Carson joined Otsuka America Pharmaceutical, Inc. in 2002 as Vice President, CNS/Aripiprazole, eventually serving as Vice President, Global Clinical Development and then Senior Vice President, Global Clinical Development at OPDC prior to his elevation to President and Chief Executive Officer, overseeing the development of Otsuka-discovered compounds. Prior to joining Otsuka, from 1998 to 2002, Dr. Carson was Group Director in Neuroscience Clinical Research and Development at Bristol Myers Squibb, or BMS. Earlier in his career, Dr. Carson was an Associate Professor and Director of the Inpatient and Partial Hospital Program at the Medical University of South Carolina. In addition to serving as Chairman of OPDC, Dr. Carson serves as a member of the board of directors of Excision BioTherapeutics, a private biotechnology company, and Internet 2, a not-for-profit organization. He is also Board Chair Emeritus of the Sphinx Organization, a not-for-profit organization advocating for parity and inclusion in the arts. Dr. Carson received an A.B. in History and Science from Harvard University and earned an M.D. from Case Western Reserve University.

How old is William Carson?

William Carson is 61, he's been the Director of Prevail Therapeutics Inc since 2020. There are 3 older and 9 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.

What's William Carson's mailing address?

William's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.

Insiders trading at Prevail Therapeutics Inc

Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson und Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.

What does Prevail Therapeutics Inc do?

Prevail Therapeutics Inc executives and stock owners

Prevail Therapeutics Inc executives and other stock owners filed with the SEC include:

• Asa Abeliovich,
  President, Chief Executive Officer, Director
• Jeffrey Sevigny,
  Chief Medical Officer
• Yong Dai,
  Chief Technology Officer
• Franz Hefti,
  Chief Development Officer
• Francois Nader,
  Independent Chairman of the Board
• Timothy Adams,
  Independent Director
• Morgan Sheng,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Carl Gordon,
  Director
• Peter Thompson,
  Independent Director
• William Carson,
  Director
• Emily Minkow,
  Chief Business Officer
• Kira Schwartz,
  General Counsel
• Brett Kaplan,
  Chief Financial Officer
• Advisors Llc Orbi Med Capit...,
  
• Acquisition Corp Eli Lilly ...,